Roche’s immunotherapy Tecentriq combined with the Swiss drugmaker’s Avastin medicine helped people with the most common form of liver cancer to live longer than with an older drug from Germany’s Bayer.
Merck & Co. Inc.’s blockbuster anti-PD-1 immunotherapy Keytruda failed a late-stage trial’s main goals of slowing disease progression and extending the life of patients with a common type of liver cancer.
Eisai and Merck announced that the U.S. FDA approved the kinase inhibitor Lenvima (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma.
Japan’s Eisai Co. Ltd. will price the company’s cancer drug Lenvima at about $16,000 for a month’s supply before discounts, after the U.S. Food and Drug Administration approved the product’s use in patients with a common form of liver cancer.
Shares of Onxeo were down more than 50 percent after the company’s Phase III liver cancer drug Livatag failed to improve survivability over standard of care.